Last Updated on October 9, 2024 by The Health Master
New Delhi: In a significant development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to pharma major Sun Pharmaceuticals to manufacture Ranibizumab for the indication, i.e. neovascular age-related macular degeneration (wet AMD).
This approval is subject to condition that the firm should carry out the Phase IV clinical study as per the guidelines for similar biologics.
Further, in accordance with the Phase IV study, the drug maker is directed to submit protocol for conduct of Phase IV study within three months of obtaining the manufacturing license.
This came in line with the proposal presented by the pharmaceutical major Sun Pharma for marketing authorization for Ranibizumab solution for injection 10mg/ml along with the Phase III clinical study report.
Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration.
Ranibizumab binds to VEGF-A with high affinity as well as its biologically active forms, such as VEGF165, VEGF121, and VEGF110. Notably, VEGF165 is the most predominant isoform in the human eye that promotes ocular neovascularization.
VEGF165 enhances vascular permeability, inhibits apoptosis, and causes endothelial-cell mobilization from the bone marrow and differentiation for angiogenesis.
Ranibizumab binds to the receptor-binding site of VEGF-A, preventing it from binding to its receptors – VEGFR1 and VEGFR2 – that are expressed on the surface of endothelial cells. Ranibizumab thereby attenuates endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Ranibizumab is marketed under brand name Lucentis. Lucentis was developed by Genentech (Subsidiary of Roche) . The company retains commercial rights in the US and Novartis has exclusive commercial rights for the rest of the world.
E-Cigarettes using synthetic nicotine come under FDA oversight
USFDA authorises first C-19 diagnostic test using breath samples
Govt wants to ease compliance burden on Pharma Industry
FDA Maharashtra issues show cause notices to 95 Pharma units
NPPA fixes retail price of 23 formulations: April 2022
FDA warns websites illegally selling Amphetamine and Dextroamphetamine
16 Pharma units get ‘stop production orders’ for norm violations
Changes in Pharma Licensing: A tour
USFDA gives approval to Aleor for Lidocaine & Prilocaine cream
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
